Prime Medicine (PRME) News Today $2.97 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.98 +0.01 (+0.51%) As of 05/22/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRME Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Prime Medicine, Inc. (NASDAQ:PRME) Receives Average Rating of "Moderate Buy" from AnalystsMay 20, 2026 | americanbankingnews.comPrime Medicine (PRME) Reports Q1 EPSMay 13, 2026 | insidermonkey.comPrime Medicine Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 7, 2026 | globenewswire.comPrime Medicine (NASDAQ:PRME) Upgraded to Sell at Wall Street ZenMay 5, 2026 | marketbeat.comPrime Medicine (NASDAQ:PRME) Stock Rating Lowered by Wall Street ZenApril 27, 2026 | marketbeat.comPrime Medicine, Inc. (NASDAQ:PRME) Given Average Rating of "Moderate Buy" by BrokeragesApril 25, 2026 | marketbeat.comPrime Medicine (PRME) Appoints Svetlana Makhni as Chief Financial OfficerApril 23, 2026 | insidermonkey.comPrime Medicine Appoints Svetlana Makhni as New CFOApril 16, 2026 | tipranks.comPrime Medicine Appoints Svetlana Makhni as Chief Financial OfficerApril 16, 2026 | globenewswire.comPrime Medicine: Prime Editing Platform and PM577 Create Compelling Risk‑Reward in Addressing Unmet Need in Wilson’s DiseaseApril 15, 2026 | tipranks.comPrime Drink Group Announces Convertible Debenture, Board Appointment and Grant of Differed Share UnitsApril 14, 2026 | globenewswire.comPrime Medicine, Inc. (PRME) Receives a Buy from JonesTradingApril 10, 2026 | theglobeandmail.comOppenheimer initiates coverage of Prime Medicine (PRME) with outperform recommendationMarch 13, 2026 | msn.comPrime Medicine, Inc. (PRME) Presents at The Citizens Life Sciences Conference 2026 TranscriptMarch 11, 2026 | seekingalpha.comPrime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash RunwayMarch 8, 2026 | insidermonkey.comAnalysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Xeris Pharmaceuticals (XERS)March 7, 2026 | theglobeandmail.comPrime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference TranscriptMarch 6, 2026 | seekingalpha.comPrime Medicine slips after Q4 updatesMarch 4, 2026 | seekingalpha.comPrime Medicine, Inc.: Prime Medicine Reports Full Year 2025 Financial Results and Provides Business UpdatesMarch 3, 2026 | finanznachrichten.dePrime Medicine Reports 2025 Results, Advances Gene Editing PipelineMarch 3, 2026 | tipranks.comPrime Medicine Reports Full Year 2025 Financial Results and Provides Business UpdatesMarch 3, 2026 | globenewswire.comPrime Medicine to Participate in Upcoming Investor ConferencesFebruary 25, 2026 | globenewswire.comJacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy CompanyFebruary 18, 2026 | insidermonkey.comPrime Medicine Advances Wilson Disease Pipeline With New Prescreening StudyFebruary 4, 2026 | tipranks.comFavourable Signals For Prime Medicine: Numerous Insiders Acquired StockJanuary 27, 2026 | finance.yahoo.comPrime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14, 2026 | seekingalpha.comPrime Medicine updates corporate strategy for Prime Editing platformJanuary 12, 2026 | tipranks.comPrime Medicine to Present at 44th Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2026 | globenewswire.comPrime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 DataJanuary 1, 2026 | finance.yahoo.comPrime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And BeyondDecember 31, 2025 | seekingalpha.comLifeSci Capital initiates Prime Medicine (PRME), highlights one-and-done potential in liver and lung diseasesDecember 31, 2025 | msn.comPrime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 DataDecember 30, 2025 | insidermonkey.comLifeSci Capital initiates coverage of Prime Medicine (PRME) with outperform recommendationDecember 24, 2025 | msn.comPrime Medicine initiated with an outperform at LifeSci CapitalDecember 23, 2025 | msn.comPrime Medicine announces NEJM publication of PM359 dataDecember 7, 2025 | msn.comPrime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous DiseaseDecember 7, 2025 | globenewswire.comPrime Medicine, Inc. (PRME) Presents at Evercore 8th Annual Healthcare Conference TranscriptDecember 2, 2025 | seekingalpha.comPrime Medicine to Present at 8th Annual Evercore Healthcare ConferenceNovember 25, 2025 | globenewswire.comPrime Medicine transferred with Neutral rating at JPMorganNovember 18, 2025 | msn.comPrime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease - SlideshowNovember 13, 2025 | seekingalpha.comPrime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease TranscriptNovember 12, 2025 | seekingalpha.comCitigroup Maintains Prime Medicine (PRME) Neutral RecommendationNovember 12, 2025 | msn.comPrime Medicine price target lowered to $4.25 from $5 at CitiNovember 11, 2025 | msn.comPrime Medicine’s Promising Advances in Gene Editing Justify Buy RatingNovember 11, 2025 | tipranks.comPrime Medicine to Present at Jefferies Global Healthcare ConferenceNovember 11, 2025 | globenewswire.comChardan Capital Maintains Prime Medicine (PRME) Buy RecommendationNovember 11, 2025 | msn.comPrime Medicine Advances Genetic Therapy Pipeline in Q3 2025November 7, 2025 | tipranks.comCORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business UpdatesNovember 7, 2025 | globenewswire.comPrime Medicine Reports Third Quarter 2025 Financial Results and Provides Business UpdatesNovember 7, 2025 | globenewswire.comPrime Medicine appoints Hawryluk as Chief Business OfficerNovember 3, 2025 | msn.com Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRME Media Mentions By Week PRME Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRME News Sentiment▼0.000.53▲Average Manufacturing News Sentiment PRME News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRME Articles This Week▼13▲PRME Articles Average Week Get the Latest News and Ratings for PRME and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Prime Medicine and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Beam Therapeutics News Today Aurinia Pharmaceuticals News Today Bausch Health Cos News Today ADMA Biologics News Today Trevi Therapeutics News Today Pharvaris News Today Mesoblast News Today Stoke Therapeutics News Today ANI Pharmaceuticals News Today Sarepta Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRME) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
